

# PONVORY<sup>®</sup> ▼ (ponesimod) PREGNANCY REMINDER CARD

Information for female patients of childbearing potential

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Please report side effects to the MHRA through the Yellow Card scheme, via the Yellow Card website [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard), the free Yellow Card app available in Apple App Store or Google Play Store.

Alternatively you can call 0800 731 6789 for free, Monday to Friday between 9am and 5pm.

Side effects should also be reported to Juvise Pharmaceuticals on  
+33 (0)4 26 29 40 00 or at [pv@juvise.com](mailto:pv@juvise.com).

By reporting side effects, you can help provide more information on the safety of this medicine.

AR-PI-00806-1

Approved by MHRA: December 2024



# Before starting PONVORY®

Read this card containing important information which is essential to ensure safe and effective use of PONVORY® and appropriately manage selective risks.

**Do not use PONVORY® if you are pregnant, breastfeeding or could become pregnant and are not using effective contraception.**

- A pregnancy test must be conducted, and negative results must be verified by your doctor before starting treatment with PONVORY®
- Your doctor will explain before treatment initiation, and regularly thereafter, the potential harmful effects of PONVORY® to the unborn baby if you become pregnant during treatment and the actions required to minimise this risk
- Talk with your doctor about reliable methods of contraception that you should use during treatment and for at least 1 week after you stop PONVORY® treatment

# If you become pregnant during treatment or within 1 week of stopping treatment with PONVORY®

If you become pregnant, suspect pregnancy or decide to become pregnant, treatment with PONVORY® must be stopped.

If you become pregnant during treatment or within 1 week following discontinuation of treatment, please report it to your doctor immediately.

Juvisé Pharmaceuticals has put in place a Pregnancy Outcomes Enhanced Monitoring (POEM) programme to collect information about pregnancy in patients exposed to PONVORY® immediately before and during pregnancy, and on infant outcomes post-delivery.

You are encouraged to enrol in the the POEM programme. Ask your doctor for more information or please contact Juvisé Pharmaceuticals on +33 (0)4 26 29 40 00 or at [pv@juvise.com](mailto:pv@juvise.com).

# While you are taking PONVORY®

- While taking PONVORY® you must not become pregnant. A pregnancy test should be repeated at suitable times during PONVORY® treatment
- You must use effective contraception during treatment with PONVORY® and for at least 1 week after treatment ends
- PONVORY® must be stopped at least 1 week before you attempt to conceive; contact your doctor, pharmacist or nurse for further medical advice regarding the risk of harmful effects to the unborn baby
- If you become pregnant, suspect pregnancy or decide to become pregnant, you should tell your doctor straight away. Treatment with PONVORY® must be stopped immediately and a follow-up appointment should be scheduled with your doctor. See information below regarding reporting pregnancy while taking PONVORY®
- You should not breastfeed while taking PONVORY®

## After stopping PONVORY®

- If you stop taking PONVORY® due to pregnancy or attempting to conceive, your multiple sclerosis symptoms may return, get worse or new symptoms may appear. Tell your doctor immediately if you experience this after stopping treatment with PONVORY®
- You should not attempt to conceive for at least 1 week after stopping PONVORY® treatment; effective methods of contraception should be continued for at least 1 week
- If you become pregnant within 1 week of stopping treatment with PONVORY®, you should tell your doctor immediately. See following information regarding reporting pregnancy while taking or within 1 week of stopping PONVORY® treatment

# Reporting of side effects

PONVORY® is a new medicine and its safety is being closely monitored. Contact your doctor, pharmacist or nurse if you experience side effects with any medication you are taking. This includes any side effects that are not listed on the information leaflet that comes with this medication.

▼ **This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.**

**Please report side effects to the MHRA through the Yellow Card scheme, via the Yellow Card website [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard), the free Yellow Card app available in Apple App Store or Google Play Store.**

**Alternatively you can call 0800 731 6789 for free, Monday to Friday between 9am and 5pm.**

**Side effects should also be reported to Juvisé Pharmaceuticals on**

**+33 (0)4 26 29 40 00 or at [pv@juvise.com](mailto:pv@juvise.com).**

**By reporting side effects, you can help provide more information on the safety of this medicine.**

**For further information, please contact**

**Juvisé Pharmaceuticals on:**

**Tel: +33 (0)4 26 29 40 00**

**Email: [ponvoryeducationalmaterial@juvise.com](mailto:ponvoryeducationalmaterial@juvise.com)**

AR-PI-00806-1

Approved by MHRA: December 2024

LABORATOIRES JUVISE PHARMACEUTICALS

149 Boulevard Bataille de Stalingrad, 69100 Villeurbanne, France